Chapter
54. Anti-Aging Breakthrough with Bioidentical Hormones
Ponce de Leon was the famous explorer who searched
for the fountain of youth, the magic waters that restored youth and vigor and reversed
aging. Although Ponce de Leon failed to
find the “fountain of youth”, Ronald A. DePinho, a Harvard professor may have
succeeded with his genetically modified mouse experiment which reversed aging
in mice. This study was published in
Nature.(1-2) The doctor used
special mice that had been genetic engineered to age rapidly. The gene that controls aging had been "knocked
out”, so these mice had accelerated aging with shrinkage (atrophy) of the
brain, spleen, loss of sense of smell, and loss of fertility with testicular
atrophy.
Left Image:
Juan Ponce De Leon, famous explorer
searched for the fountain of youth. Wood engraving 1858, courtesy of Library of
Congress Courtesy of wikimedia commons.
Reversing Aging with the "The Ponce De Leon Effect"
The next step of the aging mouse experiment was to reverse aging and make the
mice younger. This was done by giving back the missing gene that had been
“knocked out” and see if that would reverse all these signs of aging in
the mice. For this next step, the aged mice were treated with a drug
(4-OHT) which dramatically reversed the signs of aging. The aged mice were surprisingly rejuvenated.
Their shrunken brains, spleens and testes resumed normal size, and they
regained their sense of smell. The infertile males once again became
fertile, and fathered large litters. Is this the next anti-aging
breakthrough? Can this type of treatment potentially restore organ
function and reverse degenerative disease in the elderly?
What is a Telomere? Telomeres are the Biological Clock that Control Aging
De Pinho’s mouse aging experiment was based on our knowledge of the telomere which serves as a biological clock for aging and cell replication. The telomere is a strand of DNA information which shortens with each cell replication. After about 50 cell replications or so, telomere shortening instructs the cell to stop replication in a process known as "cell senescence", or the Hayflick limit.(3) Cessation of cell replication directly causes aging, senescence and death. Shortening of the telomeres hastens aging, and lengthening the telomeres halts or reverses aging, producing the Ponce De Leon, “fountain of youth” effect.
Nobel Prize for Telomere Research
Much of our knowledge of telomeres and aging is credited to the work of Carol Grieder and her colleagues, awarded the 2009 Nobel Prize in Medicine for discovery and work on telomerase, the enzyme that lengthens telomeres.(4) In 1984, Greider discovered the enzyme telomerase and later she found that telomerase can prevent shortening of the telomeres, which prevents and reverse the aging process. Her findings were published in 1985 in the journal, Cell.(5) Activating the enzyme, telomerase, protects the telomeres from shortening and serves as an anti-aging treatment, slowing or reversing aging. On the contrary, knocking out or inhibiting telomerase activity allows telomeres to shorten and accelerate aging.
The Race to Activate Telomerase
How can we activate telomerase? The answer to this question can be found in
an excellent 2002 review article by Cong entitled, “Human Telomerase and Its
Regulation".(7) Among other things, the bioidentical hormones,
17 beta estradiol (estrogen) activates telomerase.
hTERT Gene and Estrogen Activation of Telomerase
The major mechanism for control and activation of telomerase is the hTERT
promoter gene which stands for the human Telomerase Reverse Transcriptase
(hTERT) gene. When the hTERT gene is sequenced, and the code examined,
one finds two estrogen receptor elements in this gene. This explains
why 17-beta estradiol activates telomerase. The fact that there
are estrogen receptors in the hTERT gene means that estrogen
activates telomerase.(7) Estrogen
blockers such as Tamoxifen™ block these receptors and turn off
telomerase. Androgens were also found to turn on the hTERT gene and
activate telomerase, and as expected, androgen blocker drugs inhibit telomerase.(7)
Doing Genetic Gymnastics To Use
Tamoxifen™
Although
much of the scientific research on telomerase activity has focused on
estrogen (a bioidentical hormone) as the regulator and activator of
telomerase activity, the DePinho Harvard group did something different.
They genetically modified the mouse TERT gene so they could use a synthetic
hormone called 4-OHT, which is actually Tamoxifen™. Normally, Tamoxifen™
is an estrogen receptor blocker and inhibitor of telomerase
activity. The Depinho group did some genetic gymnastics and modified
the genes of the mice so the Tamoxifen™ would activate the TERT gene, rather
than inhibit it.
More on Tamoxifen™
Tamoxifen™, originally made by Astra-Zeneca, had global sales in 2001 of a billion dollars. This was a big seller, a blockbuster. As you might guess, Astra-Zeneca is a large pharmaceutical company with deep pockets for funding academic research.(8)(9) So, why did the Harvard group use a synthetic hormone called 4-OHT, to increase telomere length when research over the past decade shows that 17 Beta-Estradiol is the natural agent for this? Why not use 17-Beta Estradiol to produce the same anti-aging effects as the DePinho mouse telomere study?
Bioidentical Hormones are the Most Logical Choice
Whether you happen to be a human being
or a mouse, then the most logical and effective way to increase
telomerase activity, lengthen the telomeres and reverse aging is with the human
bioidentical hormone, 17-Beta-Estradiol, also known as estrogen. In 1999, more than a decade ago, Kyo demonstrated
that 17-Beta-Estradiol activates telomerase via direct and indirect effects on
the hTERT promoter region.(10) In
2000 Silvia Misiti showed that telomerase activity and TERT gene
expression is regulated by and dependent on 17 Beta Estradiol, which by the
way, is a Bioidentical Hormone.(11) In
2008, Bayne showed that estrogen deficiency in mice leads to
telomere shortening and rapid aging. (12) Another study in 2009 by Rodrigo T.
Calado from the NIH (National Institute of Health) showed
that 17-Beta-Estradiol was effective in increasing TERT gene expression
and telomerase enzymatic activity. Quite contrary to DePinho's mouse
aging model, the beneficial effect of 17-Beta Estradiol on telomerase function
was abolished by Tamoxifen™, an estrogen blocker drug.(13)
A recent December 2010 study from Imanishi from Japan showed that
17-Beta-Estradiol (estrogen) augments telomerase activity, thereby accelerating
recovery after injury and reducing the effects of aging (reducing
senescence). If this isn't a description of anti-aging effects, I don't
know what is.(14)(15)
Published in the journal Gut in 2004, Sato
found that Estradiol prevents telomere shortening in normal human liver cells,
as well as in a mouse model of chemically induced liver
cirrhosis. Sato states that estradiol is the preferred treatment and
superior to Dr. Depinho's genetic engineering proposals.(16)
An important study in Circulation 2006 found that 17-Beta Estradiol
enhances recovery after heart attacks by augmenting incorporation of
endothelial stem cells and inducing new collateral vessels in the ischemic
myocardium. This beneficial effect is related to telomerase
activation of the Endothelial Progenitor cells. (17)
Bioidentical Hormones Levels Decline After Age 50
Bioidentical hormones are the hormones normally found in the human body. After age 50, hormone levels decline in men and women, heralding the onset of degenerative changes also known as aging. It makes sense to replenish these hormones to normal levels which we now know activates telomere lengthening, and reverses senescence.
Why the Genetic Engineering Gymnastics ?
In real life, Tamoxifen™ is anti-estrogen and acts to inhibit telomerase activity. So, you might be wondering why DePinho's group did some genetic engineering gymnastics to get the right receptors loaded onto the TERT gene, so that Tamoxifen could be used as the promoter drug, a drug that actually blocks the effect of 17-Beta Estradiol and is a TERT inhibitor in actual real life. It's all about Big Business and Big Pharma.
Pharmaceutical Industry and a Conflict of Interest
If you are wondering if telomere research at Harvard
is tainted by Big Business and Big Pharma money, the answer is yes, of
course. It's all disclosed in the public record.(18) The anti-aging
mouse study author, Dr. DePinho received more than $83,000 dollars as a
consultant to the Glaxo-Smith Klein drug company in 2009-2010.(18) Dr
DePinho also co-founded Karyopharm, a privately held Oncology company
which raised $20 Million in financing for its line of Novel Nuclear
Transport Modulators. Dr DePinho is also one of the Directors at the
Dana-Farber Cancer Institute which recently raised 1 Billion Dollars to fund
its research activities (how much of this from Big Pharma?). So yes, of
course, there is big money and big pharma involved in the halls of academic
medicine, and this explains why a synthetic drug like 4-OHT (4 hydroxy
tamoxifen) was used in the mouse telomere study instead of the more logical
choice of 17 beta estradiol (estrogen).
The Race for Natural Substances That Activate Telomerase and Reverse Aging
Resveratrol, Silymarin and Gingko Biloba are natural
substances found to activate telomerase with potential
for anti-aging. (19-21) Calvin Harley of Geron Corporation, and John
Anderson and William H Andrews of Sierra Sciences are leading the race to
develop safe products as nutritional supplements to activate telomerase and
reverse aging. Dr. Andrews says "Telomerase activation technology promises to be the most significant
advance in human health since germ theory."(22-23)
References For Chapter 54. Anti-Aging Breakthrough
(1) http://www.nature.com/news/2010/101128/full/news.2010.635.html
Published online 28 November 2010 Nature - Telomerase reverses ageing process-
Dramatic rejuvenation of prematurely aged mice hints at potential therapy.
(2) http://www.nature.com/nature/journal/vaop/ncurrent/full/nature09603.html
Telomerase reactivation reverses tissue degeneration in aged
telomerase-deficient mice Mariela Jaskelioff,Florian L. Muller,Ji-Hye
Paik,Emily Thomas,Shan Jiang,Andrew C. Adams,Ergun Sahin,Maria
Kost-Alimova,Alexei Protopopov,Juan Cadiñanos,James W. Horner,Eleftheria
Maratos-Flier& Ronald A. DePinho Nature (2010)Published online 28 November
2010
(3)http://www4.utsouthwestern.edu/cellbio/shay-wright/publications/hayflick.nature.pdf
Hayflick, his limit, and cellular ageing Jerry W. Shay and Woodring E.Wright
Nature Reviews Mol Cell Bio 72 | OCTOBER 2000 | VOLUME 1
(4) http://www.nytimes.com/2009/10/06/science/06nobel.html
New York Times- 3 Americans Share Nobel for Medicine By NICHOLAS WADE October
5, 2009
(5) http://www.ncbi.nlm.nih.gov/pubmed/3907856
Cell. 1985 Dec;43(2 Pt 1):405-13. Identification of a specific telomere
terminal transferase activity in Tetrahymena extracts. Greider CW, Blackburn
EH.
(6) http://www.ncbi.nlm.nih.gov/pubmed/9335332
Cell. 1997 Oct 3;91(1):25-34. Telomere shortening and tumor formation by mouse
cells lacking telomerase RNA. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp
PM, DePinho RA, Greider CW. Cold Spring Harbor Laboratory, New York 11724, USA.
(7) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC120798/
Microbiol Mol Biol Rev. 2002 September; 66(3): 407–425.
Human Telomerase and Its Regulation. Yu-Sheng Cong,* Woodring E. Wright, and
Jerry W. Shay
(8) http://www.news-medical.net/health/What-is-Tamoxifen.aspx
Tamoxifen is an antagonist of the estrogen receptor in breast tissue.
Global sales of tamoxifen in 2001 were $1,024 million.
(9) http://www.womenshealthtrack.vcu.edu/pdf/Osborne.pdf
ALASTAIR J.J. WOOD , M.D., Editor Drug Therapy, Tamoxifen in the Treatment of Breast
Cancer C. Kent Osborne, M.D., NEJM 1998 Volume 339 Number 22 , 1609
(10) http://cancerres.aacrjournals.org/content/59/23/5917.full
Estrogen Activates Telomerase. Satoru Kyo1, Masahiro Takakura, Taro Kanaya,
Wang Zhuo, Kohtaro Fujimoto, Yukihito Nishio, Akira Orimo, and Masaki Inoue.
Cancer Res December 1, 1999 59; 5917
(11) http://mcb.asm.org/cgi/content/full/20/11/3764
Molecular and Cellular Biology, June 2000, p. 3764-3771, Vol. 20, No. 11
Induction of hTERT Expression and Telomerase Activity by Estrogens in Human
Ovary Epithelium Cells. Silvia Misiti, et al., Molecular Oncogenesis
Laboratory, Regina Elena Cancer Institute, Rome, Italy.
(12) http://www.ncbi.nlm.nih.gov/pubmed/18936784
Cell Res. 2008 Nov;18(11):1141-50. Estrogen deficiency leads to telomerase
inhibition, telomere shortening and reduced cell proliferation in the adrenal
gland of mice. Bayne S, Jones ME, Li H, Pinto AR, Simpson ER, Liu JP.
Department of Immunology, Central Eastern Clinical School, Monash University,
Melbourne, Australia.
(13) http://bloodjournal.hematologylibrary.org/cgi/content/full/114/11/2236
Blood, 10 September 2009, Vol. 114, No. 11, pp. 2236-2243.
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary
hematopoietic cells. Rodrigo T. Calado et al. National Institutes of Health,
Bethesda, MD
(14) http://www.ncbi.nlm.nih.gov/pubmed/19965898
Ther Adv Cardiovasc Dis. 2010 Feb;4(1):55-69. Epub 2009 Dec 4. Endothelial
progenitor cell senescence--is there a role for estrogen? Imanishi T, Tsujioka
H, Akasaka T.
(15) http://journals.lww.com/jhypertension/Abstract/2005/09000/Estrogen_reduces_endothelial_progenitor_cell.14.aspx
Journal of Hypertension:September 2005 - Volume 23 - Issue 9 - p 1699-1706
Estrogen reduces endothelial progenitor cell senescence through augmentation of
telomerase activity Imanishi, Toshio; Hano, Takuzo; Nishio, Ichiro
(16) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774098/?tool=pubmed
Gut. 2004 July; 53(7): 1001–1009. Prevention of critical telomere shortening by
oestradiol in human normal hepatic cultured cells and carbon tetrachloride
induced rat liver fibrosis. R Sato et al. Department of Pathology, Iwate
Medical University School of Medicine, Morioka, Japan
(17) http://circ.ahajournals.org/cgi/content/abstract/113/12/1605
Circulation. 2006;113:1605-1614.)
Molecular Cardiology - Estradiol Enhances Recovery After Myocardial Infarction
by Augmenting Incorporation of Bone Marrow–Derived Endothelial Progenitor Cells
Into Sites of Ischemia-Induced Neovascularization via Endothelial Nitric Oxide
Synthase–Mediated Activation of Matrix Metalloproteinase-9 Atsushi
Iwakura, MD, PhD et al.
(18) http://projects.propublica.org/docdollars/states/massachusetts
Dollars for Docs, What Drug Companies are Paying Your Doctor
(19) http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.272/abstract
Resveratrol reduces endothelial progenitor cells senescence through
augmentation of telomerase activity by Akt-dependent mechanisms L Xia, X X
Wang, X S Hu, X G Guo, Y P Shang, H J Chen, C L Zeng, F R Zhang, J Z
ChenArticle first published online: 29 JAN 2009 British Journal of Pharmacology
Volume 155, Issue 3, pages 387–394, October 2008.
(20) http://www.ncbi.nlm.nih.gov/pubmed/20838231
J Cardiovasc Pharmacol. 2010 Aug 31. [Epub ahead of print]
Silymarin Inhibits Endothelial Progenitor Cells Senescence and Protects Against
the Antiproliferative Activity of Rapamycin. Preliminary Study. Parzonko A,
Naruszewicz M.Department of Pharmacognosy and Molecular Basis of Phytotherapy,
Medical University of Warsaw, Poland.
(21) http://www.ncbi.nlm.nih.gov/pubmed/17312453
J Cardiovasc Pharmacol. 2007 Feb;49(2):111-5. Ginkgo biloba extract reduces
endothelial progenitor-cell senescence through augmentation of telomerase
activity. Dong XX, Hui ZJ, Xiang WX, Rong ZF, Jian S, Zhu CJ. Department of
Cardiology, the First Affiliated Hospital, Medical School of Zhejiang University,
Hangzhou, China.
(22) http://www.tasciences.com/pdf/Harley_CMM_final.pdf
Current Molecular Medicine 2005, 5, 29-38 205 Telomerase Therapeutics for
Degenerative Diseases. Calvin B. Harley* Geron Corporation, Menlo Park, CA,
94025, USA
(23) http://pharmalive.com/News/index.cfm?articleid=747325&categoryid=40
Sierra Sciences' Plan to Cure Aging is Validated by Newly Published Proof of
Concept Experiment . “Telomerase activation technology promises to be the
most significant advance in human health since germ theory."
Author: Jeffrey Dach MD